Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 2 Phase NA 1 Phase 4 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphangioleiomyomatosis 1

Interventions

Cisplatin 1041 Cyclophosphamide 973 Carboplatin 954 Radiotherapy 893 Bevacizumab 847 Gemcitabine 817 pembrolizumab 759 Paclitaxel 738 Docetaxel 734 Oxaliplatin 706 Capecitabine 648 Fluorouracil 564 Rituximab 559 Nivolumab 506 Dexamethasone 487 Etoposide 468 Doxorubicin 458 Irinotecan 442 Drug Therapy 402 Leucovorin 377 Cytarabine 342 Cetuximab 340 Lenalidomide 326 Trastuzumab 323 Pemetrexed 315 durvalumab 295 Filgrastim 287 Magnetic Resonance Spectroscopy 278 Temozolomide 275 Prednisone 273

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × Loratadine × Clear all

NCT05190627 2022-01-27

LORALAM

Institut d'Investigació Biomèdica de Bellvitge

Phase 2 Unknown

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡